UK regulators OK pSivida's Iluvien
The UK's National Institute for Health & Care Excellence OK's pSivida's Iluvien drug/device combo for cataract surgery patients with chronic diabetic macular edema.
pSivida said the UK's National Institute for Health & Care Excellence approved its Iluvien drug/device combination.
The approval is for cataract surgery patients who don't respond to standard treatment for diabetic macular edema, according to a press release.
"We are very pleased with NICE's recommendation, which is a key step in the availability of Iluvien for this typically large subgroup of chronic DME patients," president & CEO Dr. Paul Ashton said in prepared remarks.